Wire · opportunities
FDA Accepts NDA for Ralinepag in Pulmonary Arterial Hypertension
◆ Sectors
Drug Discovery
◆ Geography
United States
◆ Source
◆ Verified
Fusion42 · 25 August 2026 · Fusion42 review
The US FDA has accepted the New Drug Application (NDA) for ralinepag, a treatment for pulmonary arterial hypertension, signaling progression towards potential market approval.
This Wire brief sits within Fusion42's coverage of Drug Discovery, and 2 sources have reported it.
◆ ◆ The Wire takeaway
You need to accelerate regulatory preparedness if your biotech targets pulmonary hypertension. The FDA acceptance opens competitive space for treatments like ralinepag, raising the bar for trial design and go-to-market timing.
◆ Coverage
2 sources · 24 Aug 2026
◆ Related on Wire
◆ Topics
Drug DiscoveryFDAralinepagpulmonary-arterial-hypertensiondrug-approvalregulatory